Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 17/20 | 0.84 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.84 |
| ▸ | PDE4A | P27815 | 11/20 | 0.84 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.84 |
| ▸ | HTR2B | P41595 | 1/20 | 0.76 |
| ▸ | TNF | P01375 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13337346 | 1.00 | PDE4B (0.84) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL7848491 | 1.00 | PDE4B (0.84) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL476946 | 1.00 | PDE4B (0.84) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537033 | 0.93 | PDE4B (0.90) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537699 | 0.93 | PDE4B (0.90) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537255 | 0.93 | PDE4B (0.90) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL23392623 | 0.91 | PDE4B (0.87) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL21494501 | 0.91 | PDE4B (0.87) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL21494457 | 0.91 | PDE4B (0.87) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3131846 | 0.91 | PDE4B (0.87) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CD79B, BCL6, CD22 | PDE4B 4638/4885PDE4C 4515/4885PDE4A 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.